4//SEC Filing
Ahrens Brenton Karl 4
Accession 0000899243-20-001847
CIK 0001659323other
Filed
Jan 22, 7:00 PM ET
Accepted
Jan 23, 5:00 PM ET
Size
7.6 KB
Accession
0000899243-20-001847
Insider Transaction Report
Form 4
Ahrens Brenton Karl
Director
Transactions
- Award
6.500% Exchangeable Senior Subordinated Note due 2025
2020-01-21$2000000.00/sh(indirect: By Canaan X L.P)Exp: 2025-01-31→ Ordinary Shares (2,000,000 underlying)
Footnotes (3)
- [F1]On January 21, 2020, Iterum Therapeutics Bermuda Limited (the "Issuer"), a wholly-owned subsidiary of Iterum Therapeutics plc (the "Company"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the "Exchangeable Notes") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. Subject to the terms of the indenture governing the Exchangeable Notes, on or after January 21, 2021 until the second scheduled trading day immediately preceding January 15, 2025, holders may exchange the Exchangeable Notes at any time. The Exchangeable Notes are exchangeable into, at the Company's election, Ordinary Shares of the Company, cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share).
- [F2](Continued from footnote 1) The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms.
- [F3]This Exchangeable Note is held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X", and together with the Canaan Fund, the "Canaan Entities"). Investment and voting decisions with respect to the securities held by the Canaan Fund are made by the managers of Canaan X, collectively. The reporting person, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Company's board of directors. The reporting person disclaims Section 16 beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest therein, if any, in such securities by virtue of the limited liability company interests he owns in Canaan X.
Documents
Issuer
Iterum Therapeutics plc
CIK 0001659323
Entity typeother
Related Parties
1- filerCIK 0001322927
Filing Metadata
- Form type
- 4
- Filed
- Jan 22, 7:00 PM ET
- Accepted
- Jan 23, 5:00 PM ET
- Size
- 7.6 KB